FY2024 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of IQVIA in a research report issued on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $10.07 per share for the year, down from their previous estimate of $10.15. The consensus estimate for IQVIA’s current full-year earnings is $10.18 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2025 earnings at $10.91 EPS.

A number of other analysts have also issued reports on IQV. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and dropped their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Robert W. Baird reduced their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Trading Up 0.2 %

IQVIA stock opened at $191.33 on Wednesday. The company has a market capitalization of $34.73 billion, a price-to-earnings ratio of 25.11, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a 50-day moving average price of $225.08 and a 200 day moving average price of $227.79. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. PGGM Investments raised its stake in shares of IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares during the last quarter. Quadrature Capital Ltd purchased a new position in IQVIA during the 1st quarter worth $3,365,000. Simplify Asset Management Inc. lifted its stake in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the period. Raymond James & Associates increased its stake in shares of IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after acquiring an additional 5,417 shares during the period. Finally, Versor Investments LP purchased a new position in IQVIA during the third quarter worth about $1,328,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.